Management of atopic dermatitis in the pediatric population

被引:150
作者
Krakowski, Andrew C. [1 ]
Eichenfield, Lawrence F. [2 ,3 ]
Dohil, Magdalene A. [2 ,3 ,4 ]
机构
[1] Univ Calif San Diego, Div Pediat Dermatol, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA
[3] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[4] Rady Childrens Hosp, Eczema Ctr, San Diego, CA USA
关键词
topical calcineurin inhibitors; atopicdermatitis atopy; management strategies; topical steroids;
D O I
10.1542/peds.2007-2232
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Atopic dermatitis, one of the most common skin disorders in young children, has a prevalence of 10% to 20% in the first decade of life. It is a chronic illness that requires a multifaceted treatment strategy in the setting of limited therapeutic options. Balancing safety concerns with efficacious treatment is of particular importance in the pediatric population. Parents of patients with atopic dermatitis turn to their primary caregivers for guidance regarding this physically demanding and psychologically stressful condition. In addition to serving as a review of atopic dermatitis, this article delves into the state-of-the-art therapeutic options and includes a detailed review of the differences between topical corticosteroids and topical calcineurin inhibitors. We also discuss new treatment strategies that are being used by atopic dermatitis specialists, such as comprehensive "education-as-intervention" models, wet wraps, bleach baths, and systemic immunomodulatory therapies.
引用
收藏
页码:812 / 824
页数:13
相关论文
共 112 条
[1]   Changing paradigms in dermatology: Topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis [J].
Abramovits, W ;
Goldstein, AM ;
Stevenson, LC .
CLINICS IN DERMATOLOGY, 2003, 21 (05) :383-391
[2]  
Anonymous, 2007, Morbidity and Mortality Weekly Report, V56, P478
[3]  
[Anonymous], 2006, EL PRESCR INF
[4]  
*AST PHARM US INC, 2006, PROT PRESCR INF
[5]  
Baker SS, 2000, PEDIATRICS, V106, P346
[6]   Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema:: ISAAC [J].
Beasley, R ;
Keil, U ;
von Mutius, E ;
Pearce, N ;
Aït-Khaled, N ;
Anabwani, G ;
Anderson, HR ;
Asher, MI ;
Björkstéin, B ;
Burr, ML ;
Clayton, TO ;
Crane, J ;
Ellwood, P ;
Lai, CKW ;
Mallol, J ;
Martinez, FD ;
Mitchell, EA ;
Montefort, S ;
Robertson, CF ;
Shah, JR ;
Sibbald, B ;
Stewart, AW ;
Strachan, DP ;
Weiland, SK ;
Williams, HC .
LANCET, 1998, 351 (9111) :1225-1232
[7]   A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases [J].
Beattie, PE ;
Lewis-Jones, MS .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (01) :145-151
[8]   Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial [J].
Berth-Jones, J ;
Takwale, A ;
Tan, E ;
Barclay, G ;
Agarwal, S ;
Ahmed, I ;
Hotchkiss, K ;
Graham-Brown, RAC .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (02) :324-330
[9]   Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis [J].
BerthJones, J ;
GrahamBrown, BAC ;
Marks, B ;
Camp, RDR ;
English, JSC ;
Freeman, K ;
Holden, CA ;
Rogers, SCF ;
Oliwiecki, S ;
Friedmann, PS ;
LewisJones, MS ;
Archer, CB ;
Adriaans, B ;
Douglas, WS ;
Allen, BR .
BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (01) :76-81
[10]  
Boguniewicz M, 2001, J ALLERGY CLIN IMMUN, V108, P651, DOI 10.1067/mai.2001.118598